首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 4期 肝纤维化/肝硬化的可逆性及评价 => 肝纤维化及肝硬化 =>血清EBV-miR-..
血清EBV-miR-BART13-3P在青海地区慢性乙型肝炎肝纤维化患者中的表达及诊断价值
xpression of serum EBV-miR-BART13-3p and its diagnostic value in patients with chronic hepatitis B liver fibrosis in Qinghai, China
文章发布日期:2019年03月07日  来源:  作者:李萍英,杨永耿,李娟,等  点击次数:326次  下载次数:72次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的通过比较青海地区不同肝纤维化进程的慢性乙型肝炎(CHB)患者血清EBV-miR-BART13-3P表达差异,探讨血清EBV-miR-BART13-3P在青海地区CHB肝纤维化中的诊断价值。方法选取2015年7月-2017年3月期间青海省人民医院消化科收治的100例CHB肝纤维化患者及20例门诊体检正常人群,通过肝脏瞬时弹性成像检测系统(FibroTouch)进行纤维化分期(F0~4)。分为对照组(n=20)、F0~2组(n=36)、F2~4组(n=44)和肝硬化组(n=20)共4组。采用real-time PCR法检测血清EBV-miR-BART13-3P,比较各组间血清EBV-miR-BART13-3P的表达差异。计量资料多组间比较采用单因素方差分析,组间进一步比较采用LSD-t检验;计数资料组间比较采用χ2检验。采用Pearson相关分析比较血清EBV-miR-BART13-3P与肝脏硬度测定值(LSM值)的相关性,并采用受试者工作特征曲线评价血清EBV-miR-BART13-3P与肝纤维化指标[Ⅲ型前胶原(PCⅢ)、透明质酸(HA)]在CHB肝纤维化中的诊断价值。结果青海地区CHB F0~2组(8.91±2.33)、F2~4组(14.89±424)、肝硬化组(36.56±9.02)中血清EBV-miR-BART13-3P表达均高于对照组(1.01±0.57),并随着肝纤维化的进程血清EBV-miR-BART13-3P表达水平逐渐升高(F=219.42,P<0.001);血清EBV-miR-BART13-3P诊断肝纤维化的ROC曲线下面积为0970,敏感度为96.9%,特异度为88.9%,最佳临界值为10.10;PCⅢ ROC曲线下面积为0.632,敏感度为31.3%,特异度为100%,最佳临界值为47.58 ng/ml;HA ROC曲线下面积为0.670,敏感度为81.3%,特异度为55.6%,最佳临界值为85.52 ng/ml,血清EBV-miR-BART13-3P与LSM值呈显著正相关(r=0.797,P<0.001);青海地区血清EBV-miR-BART13-3P在同组CHB肝纤维化中不同民族、不同海拔间表达差异无统计学意义(P值均>0.05)。结论在青海地区随着CHB肝纤维化的进程加重,血清EBV-miR-BART13-3P表达逐渐升高;血清EBV-miR-BART13-3P在CHB肝纤维化中有较高的诊断价值;青海地区不同民族、不同海拔对血清EBV-miR-BART13-3P表达无显著影响。
【Abstract】:ObjectiveTo investigate the difference in the expression of serum EBV-miR-BART13-3p between chronic hepatitis B (CHB) patients with different liver fibrosis stages in Qinghai, China and the value of serum EBV-miR-BART13-3p in the diagnosis of CHB liver fibrosis. MethodsA total of 100 patients with CHB liver fibrosis who were admitted to Department of Gastroenterology, Qinghai Provincial People′s Hospital, from July 2015 to March 2017 were enrolled, and according to fibrosis stage (F0-F4) determined by liver transient elastography (FibroTouch), they were divided into F0-F2 group with 36 patients, F2-F4 group with 44 patients, and liver cirrhosis group with 20 patients. A total of 20 normal individuals who underwent physical examination were enrolled as control group. Real-time PCR was used to measure serum EBV-miR-BART13-3p, and the expression of serum EBV-miR-BART13-3p was compared between groups. A one-way ANOVA was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. A bivariate correlation analysis was used to investigate the correlation between serum EBV-miR-BART13-3p and liver stiffness measurement (LSM), and the receiver operating characteristic (ROC) curve was used to investigate the value of serum EBV-miR-BART13-3p and liver fibrosis indices [procollagen type Ⅲ (PCⅢ) and hyaluronic acid (HA)] in the diagnosis of CHB liver fibrosis. ResultsThe F0-F2 group, the F2-F4 group, and the liver cirrhosis group had significantly higher expression of serum EBV-miR-BART13-3p than the control group (8.91±2.33/14.89±4.24/36.56±4.24 vs 1.01±0.57, F=219.42, P<0.001). Serum EBV-miR-BART13-3p had an area under the ROC curve (AUC) of 0.970, a sensitivity of 96.9%, and a specificity of 88.9% at the cut-off value of 10.10; PⅢ had an AUC of 0.632, a sensitivity of 31.3%, and a specificity of 100% at the cut-off value of 47.58 ng/ml; HA had an AUC of 0.670, a sensitivity of 81.3%, and a specificity of 55.6% at the cut-off value of 85.52 ng/ml. Serum EBV-miR-BART13-3p was positively correlated with LSM (r=0.797, P<0.001). For the patients with the same stage of CHB liver fibrosis, there was no significant difference in the expression of serum EBV-miR-BART13-3p between the patients in different ethnic groups or living at different altitudes in Qinghai (all P>005). ConclusionThe expression of serum EBV-miR-BART13-3p is gradually increasing with the progression of CHB liver fibrosis in Qinghai. Serum EBV-miR-BART13-3p has a high value in the diagnosis of CHB liver fibrosis. Ethnic background and altitude have no marked influence on the expression of serum EBV-miR-BART13-3p.
【关键字】:肝炎, 乙型, 慢性; 肝硬化; 微RNAs; 诊断; 青海
【Key words】:hepatitis B, chronic; liver cirrhosis; micrornas; diagnosis; QINGHAI
【引证本文】:LI PY, YANG YG, LI J, et al. Expression of serum EBV-miR-BART13-3p and its diagnostic value in patients with chronic hepatitis B liver fibrosis in Qinghai, China[J]. J Clin Hepatol, 2019, 35(4): 774-779. (in Chinese)
李萍英, 杨永耿, 李娟, 等. 血清EBV-miR-BART13-3P在青海地区慢性乙型肝炎肝纤维化患者中的表达及诊断价值[J]. 临床肝胆病杂志, 2019, 35(4): 774-779.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号